Prospective observational study for the prediction of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms.

Prospective observational study for the prediction of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms. - The prediction of adverse events of triplet chemotherapy for pancreatic cancer and colorectal cancer by genetic polymorphisms.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042746

Enrollment

150

Registered

2020-12-15

Start date

2020-12-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer and colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with pancreatic cancer and colorectal cancer (resectable or unresectable)in accordance with the following criteria 1)no gender 2)age over 20 years old 3)the patients who gained written consent by the patient's free will with sufficient understanding after receiving sufficient explanation for the participation of this study 4)the patients who are scheduled to receive or are undergoing any of the following treatments a) to c) a)triplet chemotherapy (FOLFIRINOX therapy for pancreatic cancer or FOLFOXIRI therapy for colorectal cancer) b)gemcitabine plus nab-PTX therapy for pancreatic cancer c)FOLFIRI therapy or FOLFOX therapy for colorectal cancer

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
Search for the predictors of adverse events	—

Secondary

Measure	Time frame
Search for the predictors of therapeutic effects	—

Countries

Japan

Contacts

Public ContactGen Kanesada

Yamaguchi University Graduate School of Medicine Department of Gastroenterological, Breast and Endocrine Surgery

gen021eb@yamaguchi-u.ac.jp0836-22-2264

Outcome results